Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Halozyme Therapeutics, Inc.

NASDAQ: HALO · Life Sciences · 10 alerts · CIK 1159036

Share price
$96.50Close, Nov 16
Market cap
$11B
Shares outstanding
114.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Halozyme Therapeutics, Inc. filings on SEC EDGAR ↗

4:41 PM ET 8-K
Loan & Debt

Halozyme Therapeutics $1.5B Debt Financing with The Bank of New York Mellon Trust Company, N.A.

Halozyme Therapeutics completed the sale of $1.5 billion in 1.50% Convertible Senior Notes due 2033, which included a $200 million overallotment option exercised by initial purchasers. The company used the proceeds to fund capped call transactions and to repurchase approximately $652.5 million of its existing 0.25% notes due 2027 and 1.00% notes due 2028.

Value
$1.5B
Counterparty
The Bank of New York Mellon Trust Company, N.A.
Term
through 2033
8:24 AM ET 8-K
Loan & Debt

Halozyme Therapeutics $1.5B Debt Financing

Halozyme Therapeutics priced an upsized private offering of $1.3 billion in 1.50% convertible senior notes due 2033, with an additional $200 million option granted to initial purchasers. The company entered into capped call transactions to manage potential dilution, with an initial cap price representing a 90% premium over the current stock price. Proceeds are intended for general corporate purposes, which may include debt repayment or share repurchases.

Value
$1.5B
Term
through Oct 2033
4:33 PM ET 8-K
Loan & Debt

Halozyme Therapeutics $1.2B Debt Financing

Halozyme Therapeutics announced a proposed offering of $1.05 billion in convertible senior notes due 2033, with an additional $150 million overallotment option for initial purchasers. The company intends to use the proceeds to fund capped call transactions, repurchase a portion of its existing 0.25% notes due 2027 and 1.00% notes due 2028, and for general corporate purposes.

Value
$1.2B
Term
7 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.